On June 25, Boston Scientific fell 3.05% in regular trading, trading at $44.225/share, with turnover of $603 million. The stock continues to trade near its 52-week low amid intensifying analyst downgrades.

On the news front, Jefferies on June 24 slashed its target price on Boston Scientific from $100 to $67, a 33% reduction, while maintaining a buy rating. This follows Piper Sandler's earlier cut from $90 to $65, representing a 28% decrease. According to FactSet, the current average analyst target price stands at $74.67. The rapid succession of significant target price reductions has notably weighed on market sentiment, with the stock declining steadily over recent sessions.

Boston Scientific's next earnings report is scheduled for July 29 pre-market, and the market may be pricing in uncertainty ahead of the release.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)